Phase 2 Pancreatic Cancer Trial, Recruiting NCT07312422 Sponsor: Zhejiang Provincial People's Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT07312422
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender
  • People whose general health and ability to carry out daily activities falls within a certain range, measured by a standard medical scoring tool called the ECOG scale (scores 0 or 1 indicate being fully active or having only minor limitations) (confirm with trial site)
  • People who have been diagnosed with pancreatic cancer, confirmed through a tissue or cell sample test
  • People who have not previously been treated with a type of immunotherapy drug known as a PD-1 or PD-L1 inhibitor
  • People who have at least one tumour area that is suitable for radiation therapy, not including any cancer that has spread to the bones
  • People who are willing to take part voluntarily and sign a consent form

Who may not be able to join:

  • People who have previously received radiation therapy at any point
  • People who have ongoing chronic illnesses — either infectious or non-infectious — that are not well controlled, such as heart failure that does not respond to medication or high blood pressure that is difficult to manage
  • People who currently have a serious infection that is active or not well controlled
  • People who have a history of abusing substances that affect mental state and are unable to stop, or people who have a psychiatric disorder
  • Women who are pregnant or breastfeeding, or people of childbearing potential who are unwilling or unable to use effective contraception
  • People who, in the opinion of the trial doctor, have any other condition that could affect how the trial is run or how the results are understood

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13666601475

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Zhejiang Provincial People's Hospital
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
30 April 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ORR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov